- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00744393
The Effect of Sodium Oxybate on Sleep Architecture
The Effect of Sodium Oxybate on Sleep Architecture in Critically Ill Patients: A Double-Blind, Crossover Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Sleep is disrupted in the critically ill and may lead to impaired neurocognitive function, decreased immune function, increased protein catabolism, and may compromise the ability to wean patients from mechanical ventilation. Critically ill patients may appear to sleep throughout most of their stay, but their quality of sleep is different from that of a normal healthy subject.Critically ill patients spend more time in the wakefulness stages of sleep (Stage 1 and 2) at the expense of the restorative stages (Stage 3 and 4) and REM sleep. These patients also experience an increased number of arousals and awakenings. Various factors are thought to be the cause of abnormal sleep architecture: ICU environment, pain, illness severity, psychosocial stress, medications, and mechanical ventilation.
Sodium oxybate (Xyrem®) is the sodium salt of the central nervous system depressant γ-hydroxybutyric acid (GHB) and is currently approved for use in narcoleptic patients to improve cataplexy and excessive daytime sleepiness.
Studies evaluating the use of sodium oxybate in narcoleptic patients suggest that sodium oxybate is effective at increasing slow-wave sleep, sleep efficiency, sleep latency, and REM-sleep efficiency, while also decreasing REM-sleep latency, stage 1 NREM sleep and sleep fragmentation.3, 16-19 Currently there is a lack of data evaluating the effects of sodium oxybate on sleep in critically ill patients. Obtaining evidence that sodium oxybate improves sleep architecture in the critically ill, may provide the foundation to complete future studies evaluating the effect of sodium oxybate on clinical outcomes such as duration of mechanical ventilation and length of ICU stay. Based on sodium oxybate's ability to improve sleep architecture in narcoleptic patients along with the fact that critically ill patients have similar disrupted sleep architecture, it's postulated that sodium oxybate may improve the sleep architecture in critically ill patients.
Study Type
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Mechanically ventilated ≥ 24º on an AC mode
- Placement of enteral or gastric tube (Note: these tubes will not be placed exclusively for the purposes of the study.)
- Tolerating enteral nutrition via either the stomach or small intestine (≥20mL/hr for ≥ 12 hours)
Exclusion Criteria:
- Anticipated duration of mechanical ventilation ≤72º (as per MICU team estimate)
- Riker SAS ≤ 2 (as determined by patient's nurse and/or study investigator)
- History of irreversible brain disease consistent with severe dementia based on MICU service admission note
- Admitted with a primary neurological condition (e.g. intracranial hemorrhage)
- History of seizure disorder or intracranial surgery
- History of myocardial infarction in prior 6 months
- Pregnancy (all women of child bearing potential will undergo a serum pregnancy test prior to study consent)
- Administration of a scheduled benzodiazepine as either a continuous drip or given by IVP
- Acute alcohol withdrawal
- AST/ALT >2 times ULN, INR >2 or T bilirubin > 1.5
- Current or prior use of sodium oxybate in the -past 30 days.
- Hypernatremia with a serum sodium >150
- Current use of the following hypnotics: barbiturates, melatonin, zolpidem, eszopiclone, or zaleplon
- Use of neuromuscular blocking agents
- Allergy to sodium oxybate
- Known succinic semialdehyde dehydrogenase deficiency
- History of periodic limb movement disorder.
- A prognosis considered to be hopeless (as per MICU team)
- Inability to obtain informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
Active drug
|
The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses.
The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
Other Names:
|
Placebo Comparator: P
Placebo drug
|
The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses.
The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To gain a better understanding of the effect of sodium oxybate on the following components of sleep architecture: % time in sleep stage and arousals and awakenings
Time Frame: 72 hours
|
72 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To observe any short-term adverse effects of sodium oxybate in mechanically ventilated ICU patients
Time Frame: 72 hours
|
72 hours
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Carolyn D'Ambrosio, MD, Tufts Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEMC-8479
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mechanically Ventilated ICU Patients
-
Shaare Zedek Medical CenterUnknownMechanically Ventilated ICU PatientsIsrael
-
Centre Hospitalier Universitaire BrugmannUnknown
-
Fayoum University HospitalCompletedMechanically Ventilated PatientsEgypt
-
Makerere UniversityUnknownMechanically Ventilated PatientsUganda
-
ArcheonRecruitingMechanically Ventilated PatientsFrance
-
University of ChicagoCompletedMechanically Ventilated ICU PatientsUnited States
-
Damanhour UniversityNot yet recruitingMechanically Ventilated Patients
-
Wuhan Union Hospital, ChinaYichang Humanwell Pharmaceutical Co., Ltd., ChinaCompletedMechanically Ventilated PatientsChina
-
Assistance Publique - Hôpitaux de ParisTerminated
-
University Hospital, LimogesCompleted-Mechanically Ventilated PatientsFrance
Clinical Trials on sodium oxybate
-
Jazz PharmaceuticalsCompleted
-
Kristina SimonyanNational Institutes of Health (NIH); National Institute on Deafness and Other...CompletedSpasmodic Dysphonia | Voice TremorUnited States
-
University Hospital, GhentUCB PharmaWithdrawn
-
Baylor College of MedicineJazz PharmaceuticalsCompleted
-
St. Luke's Hospital, Chesterfield, MissouriJazz PharmaceuticalsCompleted
-
Orphan MedicalCompletedNarcolepsyUnited States, Canada, Switzerland
-
Jazz PharmaceuticalsCompleted
-
UCB Pharma SACompletedNarcolepsy With CataplexyBelgium
-
National Center for Complementary and Integrative...CompletedHot Flashes | Osteoporosis, Postmenopausal | PostmenopauseUnited States
-
Brigham and Women's HospitalWithdrawnTraumatic Brain Injury | Narcolepsy | HypersomniaUnited States